Hey Folks, I know I typically only trade ETFs with TopStockPicks but we all know there are a lot of other ways to make money in the markets.
As I have gotten to know Kyle Dennis over the past few months I can say that I am truly impressed with him. He’s an incredible trader, so you should listen to what he says.
Kyle studies the biotech sector like no one else I know. He knows where to find the most useful info that I never find out about… until AFTER the trade has exploded. Here’s an update he put together for us and I thought I would share it with you tonight.
*********************
Wow, the power of biotechs!
I wanted to bring to your attention a few stocks that had news recently to show you why the biotech sector is truly the most lucrative in the stock market.
The biotech sector has the best combination of binary news events, acquisitions, and catalyst trades.
If you fish in the right pond, you are bound to hit big winners on a few of these throughout the year.
Aerie Pharmaceuticals (AERI) was a stock that we had on our watch list. They just announced positive Phase 3 data yesterday and the stock skyrocketed over 60% in one day.
We also had a buyout of Vitae Pharmaceuticals (VTAE) by Allergan for $639 Million! This was about a 158% gain in 1 day when the buyout was announced. I also know a few of you hit the buyout on Raptor Pharmaceuticals (RPTP) this week for big gains. Congrats!
Aralez Pharmaceuticals (ARLZ) was a stock we have been tracking together over the last two months from $3.50. The stock saw a high of $6.80 on the catalyst trade up to its FDA approval date. If timed perfectly, you could make a 94% gain in little over a month. Many of you messaged me with big time wins on this name, so congrats here as well!
I love the biotech sector because there are so many companies out there with the potential for huge gains. You won’t hit them all, but a few of these a year can be life changing.
I’ll be back tomorrow with a portfolio update and some stocks we should be following closely going forward.
Cheers,
Kyle Dennis
No comments:
Post a Comment